Mankind Pharma sets a new benchmark, launching 120 Premium DMF quality drugs for Indian patients

29 August 2023
mankind_pharma_small-1-

Shares of Indian generic drugmaker Mankind Pharma (BSE: 543904) edged up 1% today, after it boasted a significant stride with the introduction of 120 DMF (Drug Master File) Quality Medicines in the Indian market.

Committed to delivering exceptional healthcare solutions at affordable rates, Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre, the company noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Generics